Background: Bovine jugular vein (BJV) grafts (Medtronic, Inc, Minneapolis, Minn) are used to restore right ventricle-to-pulmonary artery continuity. Recent studies have associated these grafts with the development of infective endocarditis. The purpose of this study was to report the incidence of endocarditis in BJV grafts.
Bovine jugular vein grafts are routinely used to restore right ventricle-to-pulmonary artery continuity. In this article we report on a long-term follow-up of 253 bovine jugular vein grafts. We encountered a 10% incidence of endocarditis at a median of 7.5 years after surgery. Freedom from endocarditis at 10 years was only 77%. This high incidence of late endocarditis is concerning and warrants intervention.
See Editorial Commentary page 735.
A large spectrum of congenital heart conditions require reconstruction of the right ventricle-to-pulmonary artery (RV-PA) continuity, which is usually achieved with the use of valved conduits. The question of the ideal RV-PA conduit has been extensively investigated, and needless to say a perfect RV-PA conduit does not exist. 1 In 1999, the Contegra bovine jugular vein (BJV) graft (Medtronic, Inc, Minneapolis, Minn) was proposed for right ventricular outflow tract reconstruction. The Contegra conduit is a glutaraldehyde fixed heterologous BJV graft, containing a naturally integrated trileaflet valve and natural sinus slightly larger in diameter than its lumen. Its preparation includes a final sterilization step, performed using a proprietary sterilant that contains 1% glutaraldehyde and 20% isopropyl alcohol, in which the conduit is preserved and packaged until use. The Contegra is available in sizes between 12 and 22 mm. Because of its encouraging initial results in clinical trials, it quickly gained popularity as a possible alternative to the homograft. [2] [3] [4] Several studies have reported an unexpected occurrence of graft failure, 5, 6 whereas others have reported similar or even better behavior compared with homografts. 7, 8 In 2016 we published our experience with implantation of 792 valved conduits in the RV-PA position, among which 245 were BJV grafts. Despite finding that BJVs were associated with a lower risk for reintervention (P <.0001) and replacement (P ¼ .0002) than homografts, 14 BJV graft conduits developed endocarditis at a median of 7.5 years (34 days to 10 years) after surgery. After adjusting for other variables, the use of BJVs was found to be the sole significant risk factor associated with endocarditis and it was associated with a 9 times greater risk of endocarditis compared with homografts. 9 Over the past 3 years we have encountered a concerning increasing incidence of late endocarditis in patients with BJV grafts. This concern has been raised by recent series as well. [10] [11] [12] [13] Accordingly, the goal of this study was to evaluate the incidence of late endocarditis in patients who underwent placement of bovine jugular vein grafts in the RV-PA position.
METHODS
The study cohort included all patients who underwent surgical placement of a BJV graft at Texas Children's Hospital between 2001 and 2017. The study was approved by Baylor College of Medicine's institutional review board (date and number of approval: September 2, 2016, H-15017), and informed consent was waived. All demographic and clinical data were retrospectively collected via review of all medical records, operative reports, procedure notes, discharge notes, and clinic notes. Follow-up was obtained through a combination of clinic notes and telephone interviews of patients, families, and referring physicians. Perioperative mortality was defined as death within 30 days after surgery or before hospital discharge.
For a subanalysis of data, comparing the risk of endocarditis between conduits, homografts (pulmonary and aortic), and porcine heterograft (Hancock bioprosthetic valved conduit; Medtronic, Inc) were also included. All homografts were cryopreserved and provided by LifeNet (Virginia Beach, Va), CryoLife (Kennesaw, Ga), or RTI/Alabama Tissue Bank (Birmingham, Ala).
Valved conduits arising from a morphological left ventricle in the setting of congenitally corrected transposition of the great arteries were included in the study. The cohort was divided into the following diagnostic groups: pulmonary atresia with ventricular septal defect with or without major aortopulmonary collaterals, truncus arteriosus, Ross procedure, and other (ie, history of nonconduit tetralogy of Fallot repair, absent pulmonary valve syndrome, pulmonary atresia with intact ventricular septum, double-outlet right ventricle, and transposition of the great arteries with pulmonary stenosis or atresia). Endocarditis was defined as possible or definitive on the basis of the modified Duke criteria.
14 Pathologic diagnosis was defined as a positive culture from a vegetation or histopathology consistent with infective endocarditis.
Data Analysis
All analyses were performed for each conduit rather than for each patient. Descriptive analyses were performed for the entire cohort. Data are described as percentages and medians with ranges, as appropriate. Univariate analyses for freedom from endocarditis were performed using the Kaplan-Meier method and log rank test. The event endocarditis was registered when the diagnosis of endocarditis was made. For analysis of freedom from endocarditis, noninfected conduits were censored at the time of surgical replacement or placement of a transcatheter pulmonary valve. For patients who died, conduits were censored at the time of death.
To assess risk factors for endocarditis, parametric survival analysis models were created. Variables included were age, conduit size, diagnosis, genetic syndromes, and the conduit type (BJV grafts, homografts, and porcine heterografts). Because the analysis was done according to conduit rather than according to patients, events were modeled as repeated occurrences by including a variable of conduit placement versus replacement in the models. Results are reported as coefficients with standard errors and corresponding hazard ratios with 95% confidence intervals. A P value <.05 was considered statistically significant. All analyses were carried out using SAS for Windows version 9.4 (SAS Institute Inc, Cary, NC).
RESULTS
A total of 228 patients underwent placement of 253 BJV grafts (Table 1) ; 203 and 25 patients had 1 and 2 BJV grafts, Median conduit size, mm (range) 16 (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) respectively. The median age at conduit placement was 4 years (range, 3 days to 54 years). The number of conduits implanted increased from 2001 to 2010, after which they gradually began to decrease ( Figure 1 ). Among the 228 patients, 62 (27%) had an identified genetic syndrome or chromosomal abnormality. During a median 6.5 years (range, 3 days to 16 years) of follow-up, 6 (2.6%) of 228 patients died, including 2 (0.9%) perioperative deaths, none of which were related to infective endocarditis. The summary of the deceased patients is shown in Table 2 . A total of 131 (52%) primary conduit placements and 122 (48%) conduit replacements were performed. From the 122 conduit replacements, 44 were referred to our center after conduit placement at other institutions and 78 were performed after a previous conduit implantation at our center including: 53 homografts, 24 BJV conduits, and 1 porcine heterograft. The median duration of conduit follow-up was 6 years (range, 3 days to 14 years).
Endocarditis
During the follow-up period, 25 BJV grafts developed endocarditis at a median of 7.5 years (range, 34 days to 14 years) after surgery. Of the 25 patients who developed endocarditis, only 1 (4%) patient had a dental procedure within the month before diagnosis. Median age at endocarditis was 13 (range, 1-21) years and 11 (44%) were female. Patients exhibited clinical symptoms for a median duration of 21 days (range, 3-180 days) before the diagnosis of endocarditis was made. Four patients (16%) were asymptomatic at the time of presentation, whereas 2 (8%) presented in shock, the 19 remaining patients (76%) had nonspecific symptoms such as low-grade fever or malaise. Endocardial involvement was present in 20 patients (80%), 18 (72%) had vegetations on echocardiography, 4 (16%) had emboli, and 4 (16%) had vascular phenomena. No patient presented with immunologic phenomena (Table E1) .
Endocarditis was classified as definitive in 22 (88%) and possible in 3 (12%) according to Duke modified criteria for infective endocarditis.
14 Blood cultures were positive in 22 patients (88%) with infected conduits. The most common infectious agents were viridans streptococci (n ¼ 13; 59%). Other pathogens included methicillin-sensitive Staphylococcus aureus (n ¼ 3, 14%), Haemophilus parainfluenzae (n ¼ 2; 9%), methicillin-resistant S aureus (n ¼ 1; 4.5%), Granulicatella adiacens (n ¼ 1; 4.5%), Cardiobacterium hominis (n ¼ 1; 4.5%), and Aggregatibacter actinomycetemcomitans (n ¼ 1; 4.5%). A pathologic diagnosis was made in 13 patients (52%) with infected BJV grafts. In the remaining 10 conduits without pathologic diagnosis, a pathologic report was not available in 7 and signs of chronic inflammation and calcification were found in 3.
The overall incidence of endocarditis among BJV grafts was 10% at a median follow-up of 7.5 years, compared with 0.8% (4 of 507) of the homografts and 2.9% (5 of 169) of the porcine heterografts, and it increased over time after 2010 (Figure 1 ). Five-and 10-year freedom from endocarditis rates among BJV grafts was 97%, and 77%, respectively, significantly different from that of homografts ( Figure 2 ). After multivariable analysis, BJV grafts remained the only risk factor for developing endocarditis, with a hazard ratio of 15.7 (95% confidence interval, 4.9-50.7; Table 3 and Figure E1 ).
The management of endocarditis was surgical in 23 (92%) cases, and medical in 2 (8%). Two patients who were managed medically exclusively with antibiotics had complete resolution of symptoms. Of the 23 surgically replaced infected conduits, 19 (83%) were replaced with homografts, 3 (13%) with BJV grafts, and 1 (4%) with a porcine heterograft. Median duration of antibiotic therapy was 6 weeks (range, 4-11 weeks) for the 25 conduits that developed endocarditis. After endocarditis, there were no mortalities or recurrence of endocarditis at a median of 2 years (range, 1 month to 7 years), independent of treatment strategy.
Replacement
A total of 76 (30%) BJV grafts required surgical replacement (n ¼ 63; 83%) or transcatheter pulmonary valve implantation (n ¼ 13; 17%). Of those conduits that required replacement, 12 (19%) were replaced with porcine heterografts, 25 (40%) with homografts, 24 (38%) with BJV grafts, and 2 (3%) with other types of conduit. Five-and 10-year freedom from replacement rates were 84% and 49%, respectively. During the study period, 7 of the conduits had stents placed at a median of 3.3 years (range, 4 months to 9 years) after implantation, 2 of these conduits later developed endocarditis at 3 and 9 years, respectively, after stenting.
DISCUSSION
This study represents one of the largest singleinstitutional experiences with the use of BJV graft conduits for right ventricular outflow tract reconstruction. The main finding of this study was an alarming 10% incidence of late endocarditis affecting BJV grafts (Video 1).
Because of its availability, easy manipulation in the operating room, and wide range of sizes, the BJV graft has gained popularity as an alternative option to homografts for the treatment of congenital heart defects, and valvular heart disease. 4, 15 Another potential advantage of this conduit is its longer durability, although this finding still CAVC, Complete atrioventricular canal; ToF, tetralogy of Fallot; PA, pulmonary artery; LCA, left coronary artery; IM, intramural; CHF, congestive heart failure; L-TGA, congenitally corrected transposition of the great arteries; VSD, ventricular septal defect; PS, pulmonary stenosis; BDG, bidirectional Glenn; AVMs, arteriovenous malformations; ToF-PA, tetralogy of Fallot with pulmonary atresia; LAD, left anterior descending; RCA, right coronary artery; ECMO, extracorporeal membrane oxygenation; BT, Blalock-Taussig; NEC, necrotizing enterocolitis; CHARGE, coloboma, heart defects, atresia choanae, growth retardation, genital abnormalities, and ear abnormalities; G-tube, gastrostomy tube. *After surgical intervention. yPerioperative death.
FIGURE 2. Kaplan-Meier curves depicting freedom from endocarditis according to conduit type. Bovine jugular vein grafts had a significantly higher incidence of endocarditis than homografts and porcine heterografts (P<.001). The number of infected bovine jugular vein grafts drastically increases after 7 years of conduit implantation.
remains controversial, with contradicting evidence in the literature. [16] [17] [18] [19] In a multi-institutional propensity-matched study of 107 infants with truncus arteriosus, Hickey and colleagues reported that BJV grafts were associated with a lower risk for replacement than homografts. 20 Similar to that study, we have also reported that BJV grafts are associated with a lower rate of reintervention and replacement after adjusting for significant covariates. 9 Thereby, BJV might still have a role, especially in small patients where a conduit replacement is expected in <7 years, small-sized homografts are not readily available, and other stented bioprostheses might be too rigid to use. Despite these potential advantages of BJV grafts, recent studies, including our own institutional experience, have raised the concern regarding the increasing incidence of endocarditis of up to 11.3% in these grafts. 9, 10, 12, 13, 21 As shown in Figure 1 , our institution began to adopt the use of BJV grafts during the first 10 years after it became available. The first 3 cases of endocarditis occurred in 2010, after which the number of infected grafts began to increase. Accordingly, the number of conduits implanted began to decrease, and after our own institutional results were explored in 2015 (published in 2016), which elucidated concise data about the growing incidence of infection of these conduits, our practice shifted toward the use of other available conduits whenever possible.
In our previous report, the incidence of endocarditis among BJV grafts was 6% (14 conduits), at a median follow-up of 7 years over a 13-year period. 9 In that report, the use of BJV grafts was associated with a 9 times greater risk of endocarditis compared with that of homografts (P ¼ .006). Calculated estimates suggested that as many as 17% of patients with a BJV graft would develop endocarditis at 10 years after conduit placement, and that risk seems to increase with time. Since then, after an additional 2.5-year follow-up period, 11 more patients have developed endocarditis, raising the overall incidence of BJV graft endocarditis to 10%, and an estimate of 23% endocarditis incidence at 10 years of follow-up. During this additional follow-up time, there were no homograft or porcine heterograft conduits that developed infective endocarditis. These findings stand alongside that of other series. Ugaki and colleagues analyzed 244 BJV grafts and 135 homografts with a median follow-up of 3.4 years, and reported that 9.4% of BJV grafts became infected during the follow-up period, compared with 0.7% of the homografts. 10 The highest incidence of BJV graft endocarditis reported in the literature is that of Albanesi et al in Switzerland, with an incidence of 11.3% over an 11-year period and a median follow-up of 7.6 years. 13 Various possible hypotheses have been raised for the increased incidence of endocarditis among BJV grafts. Jalal et al reported bacterial adhesion to be higher on the BJV wall for S aureus 22 and Delmo-Walter et al reported that histologic examination of an explanted BJV graft revealed an acellular homogenous material with fragile, diffuse, and complex collagenization throughout the BJV grafts, and inflammatory tissues. 23 This might be a result of the anticalcification treatment that the conduit undergoes, which might minimize endothelial surface growth. 4 These factors might contribute to flow turbulence and thrombus formation, increasing the risk of infection. 16 Somewhat contradictory is the recent report from Veloso et al, who showed similar adherence of 3 bacterial strains to small pieces of bovine pericardial patches, BJV, and cryopreserved homografts, 24 however, these are in vitro studies using commercially available strains analyzing short-term adhesions, and thereby might not reflect long-term adhesion. 25 The longevity of the conduit has also been proposed as a substrate for graft endocarditis, with the hypothesis that this complication is more likely to occur the longer the graft remains in place 9, 10 ; this likely explains why previous studies focused on mid-term outcomes and shorter followup of BJV grafts might have not been able to detect higher rates of endocarditis in these conduits.
Transcatheter pulmonary valve replacement, which is essentially a BJV graft within a stent has raised similar concerns. A large multicenter study showed a 92% freedom from endocarditis at 4 years. 26 Van Dijck et al reported a similar 5-year survival free from endocarditis for transcatheter pulmonary valves and BJV grafts (84.9% vs 87.8%), significantly lower than that of homografts (98.7%). 27 With increasing use of transcatheter pulmonary valves, the risks associated with these should be further elucidated.
An important finding of the present study is the dramatic increase in incidence of endocarditis after 7.5 years of conduit implantation. This is evidenced in Figure 2 , which shows that at 5-year follow-up, there is no significant difference in the number of endocarditis events between conduit types, a freedom from endocarditis estimate of 97%. However, at 7.5 years after conduit implantation, the number of events in the BJV graft group drastically increases, decreasing the 10-year estimated freedom from endocarditis to 77%, which is significantly different than that of other conduit types.
Such unraveling findings have important implications for patients who have undergone implantation of this grafts. These results warrant increased surveillance in these patients. We suggest that any patient who has undergone implantation of a BJV graft in the past, especially those who have had these grafts in place for more than 6 or 7 years, be followed-up closer and undergo a thorough evaluation by their cardiologists, to detect early signs and symptoms of infection or graft failure, which might be a surrogate for turbulent flow, further increasing the risk of endocarditis. 16 Furthermore, if a patient presents with malaise or lowgrade fever, there should be a higher index of suspicion for endocarditis in the differential diagnosis, and a more thorough evaluation, including echocardiography and blood culture drawing, should be performed. 10, 28 Another interesting finding in our study is the relative indolent clinical course of the patients who were diagnosed with BJV graft endocarditis. More than 50% of these patients had low-grade fevers, malaise, and other nonspecific symptoms for several months, with 1 patient having symptoms for up to 6 months. This might have, in some instances, delayed their presentation for evaluation and diagnosis. Looking back at some of these patients, they had even been seen several times by their primary care physicians, before presenting to our institution, and the diagnosis had been missed. This might help explain the median time of symptoms duration of 21 days, which is higher than that reported with other type of infected conduits. 9 The current American College of Cardiology/American Heart Association guidelines for intervention in patients with infective endocarditis of prosthetic valves recommend early surgical intervention in cases in which valve dysfunction results in symptoms of heart failure, when infection is complicated by heart block, or persistent infection after appropriate antibacterial therapy. 29 Albanesi et al concluded that surgery was the therapy of choice for infected BJV grafts, with 83% of their patients undergoing surgical replacement of the infected conduits. 13 Similar to those findings, in our own series, 92% of the patients underwent surgical intervention to replace the infected conduit, with no surgical morbidity or mortality. These findings suggest that surgical therapy is a safe and the recommended treatment strategy for these patients. The decision as to which treatment strategy to pursue, as well as the timing of surgical intervention, whenever surgery is the treatment of choice, should be made by a multidisciplinary team including cardiologists, infectious disease specialists, and cardiothoracic surgeons.
Limitations
This study has multiple limitations, mainly related to its retrospective nature. The number of BJV grafts implanted at our institution decreased in the past 2.5 years, after the findings of our previous study. The present investigation is the result of a single institutional experience and as such, results might vary in different institutions. However, this might also be one of its strengths because the conduit selection, management strategy, and follow-up is more uniform than in retrospective multi-institutional studies.
CONCLUSIONS
In conclusion, in this large single-institutional cohort, we found a concerning 10% incidence of late endocarditis affecting BJV grafts, which appears to increase after 7 years of conduit implantation. Because of the increased risk for endocarditis and the relative indolent course of the initial disease, a more adherent and frequent clinical follow-up is warranted in patients who have undergone placement of a BJV graft in the past, especially those who have had a graft in place for more than 7 years. When endocarditis is diagnosed, surgical intervention is a safe strategy, and might alleviate the morbidity and mortality related to endocarditis with excellent outcomes.
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The Journal of Thoracic and Cardiovascular Surgery c Volume 156, Number 2 734.e1 
